CD274 and head and neck squamous cell carcinoma: Clinical trials are currently conducted combining ATR and Chk1 inhibitors with anti-PD-(L)1 antibodies in solid tumors including HNSCC (NCT04266912, NCT02264678, NCT04095273, NCT03495323) [246].